Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 4/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.32 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.32 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | GRM8 | O00222 | 1/20 | 0.32 |
| ▸ | GRM6 | O15303 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.32 |
| ▸ | PLCB1 | Q9NQ66 | 1/20 | 0.32 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.32 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1633778 | 0.83 | MGLL (0.32) | MGLLKCNH2HRH3 | |
| SCHEMBL1635220 | 0.73 | FPR3 (0.30) | — | |
| SCHEMBL4661895 | 0.73 | — | — | |
| SCHEMBL6266090 | 0.72 | CYP1A2 (0.39) | HSD11B1GRM2GRM3GRM4CYP1A2 | |
| SCHEMBL301094 | 0.72 | — | — | |
| SCHEMBL1634054 | 0.72 | LMNA (0.39) | GRM2GRM3GRM4CYP1A2ALOX15 | |
| SCHEMBL20985243 | 0.71 | — | — | |
| SCHEMBL20985252 | 0.71 | — | — | |
| SCHEMBL301224 | 0.71 | — | — | |
| SCHEMBL27659968 | 0.71 | GRM4 (0.55) | GRM2GRM3GRM4CYP1A2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1558230-B1 | SPIROCYCLOPROPYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LAB (US) | 2008-12-31 | — | — | EP | claimed |
| EP-1558230-A1 | SPIROCYCLOPROPYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS | Abbott Laboratories (US) | 2005-08-03 | — | — | EP | claimed |
| US-20040204396-A1 | Spirocyclopropyl amides and acids and their therapeutic applications | ABBVIE INC. | 2004-10-14 | — | — | US | claimed |
| WO-2004037240-A1 | SPIROCYCLOPROPYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LABORATORIES (US) | 2004-05-06 | — | — | WO | claimed |
| US-20040077616-A1 | Spirocyclopropyl amides and acids and their therapeutic applications | ABBOTT LABORATORIES | 2004-04-22 | — | — | US | claimed |
| US-7932245-B2 | Spirocyclopropyl amides and acids and their therapeutic applications | ABBOTT LABORATORIES (US) | 2011-04-26 | — | — | US | disclosed |
| EP-1558230-B1 | SPIROCYCLOPROPYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LAB (US) | 2008-12-31 | — | — | EP | disclosed |
| EP-1558230-A1 | SPIROCYCLOPROPYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS | Abbott Laboratories (US) | 2005-08-03 | — | — | EP | disclosed |
| US-20040204396-A1 | Spirocyclopropyl amides and acids and their therapeutic applications | ABBVIE INC. | 2004-10-14 | — | — | US | disclosed |
| WO-2004037240-A1 | SPIROCYCLOPROPYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LABORATORIES (US) | 2004-05-06 | — | — | WO | disclosed |
| US-20040077616-A1 | Spirocyclopropyl amides and acids and their therapeutic applications | ABBOTT LABORATORIES | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077616-A1 | Spirocyclopropyl amides and acids and their therapeutic applications | SCN1A, SCN1B, SCN10A | HSD11B1 72/4885GRM2 93/4885GRM3 176/4885 |
| US-20040204396-A1 | Spirocyclopropyl amides and acids and their therapeutic applications | SCN1A, SCN1B, SCN10A | HSD11B1 72/4885GRM2 93/4885GRM3 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.